Novavax, Inc (NVAX) concluded trading on Thursday at a closing price of $7.26, with 2.6 million shares of worth about $18.88 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.37% during that period and on March 27, 2025 the price saw a loss of about -1.76%. Currently the company’s common shares owned by public are about 160.42M shares, out of which, 146.57M shares are available for trading.
Stock saw a price change of -5.96% in past 5 days and over the past one month there was a price change of -0.82%. Year-to-date (YTD), NVAX shares are showing a performance of -9.70% which increased to 50.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.81 but also hit the highest price of $23.86 during that period. The average intraday trading volume for Novavax, Inc shares is 4.28 million. The stock is currently trading -7.98% below its 20-day simple moving average (SMA20), while that difference is down -11.14% for SMA50 and it goes to -31.72% lower than SMA200.
Novavax, Inc (NASDAQ: NVAX) currently have 160.42M outstanding shares and institutions hold larger chunk of about 59.79% of that.
The stock has a current market capitalization of $1.17B and its 3Y-monthly beta is at 3.11. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 0.97. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 3.11% while standing at 6.85% over the month.
Stock’s fiscal year EPS is expected to rise by 81.77% while it is estimated to increase by 342.99% in next year. EPS is likely to grow at an annualized rate of 67.92% for next 5-years, compared to annual growth of 25.88% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on February 28, 2025 offering a Buy rating for the stock and assigned a target price of $19 to it. Coverage by JP Morgan stated Novavax, Inc (NVAX) stock as an Underweight in their note to investors on July 30, 2024, suggesting a price target of $8 for the stock. On May 10, 2024, JP Morgan Upgrade their recommendations, while on May 10, 2024, BofA Securities Upgrade their ratings for the stock with a price target of $12. Stock get a Buy rating from B. Riley Securities on August 09, 2023.
